MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer

[1]  T. Irimura,et al.  Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosis , 2005, International journal of urology : official journal of the Japanese Urological Association.

[2]  D. Carson,et al.  MUC1 expression in human prostate cancer cell lines and primary tumors , 2005, Prostate Cancer and Prostatic Diseases.

[3]  A. Perkins,et al.  MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate , 2004, British Journal of Cancer.

[4]  Yong Li,et al.  Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates. , 2004, International journal of radiation oncology, biology, physics.

[5]  R. Figlin,et al.  Phase I Trial of Antigen-Specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-Positive Patients With Advanced Prostate Cancer , 2004, Journal of immunotherapy.

[6]  M. Poupon,et al.  Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft , 2004, British Journal of Cancer.

[7]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[9]  F. Saint,et al.  MUC6 Is a Marker of Seminal Vesicle-Ejaculatory Duct Epithelium and Is Useful for the Differential Diagnosis With Prostate Adenocarcinoma , 2003, The American journal of surgical pathology.

[10]  F. Habib,et al.  MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue , 2003, BJU international.

[11]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[12]  M. Ghazizadeh,et al.  Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. , 2002, Japanese journal of clinical oncology.

[13]  N. Bander,et al.  In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen , 2002, Prostate Cancer and Prostatic Diseases.

[14]  J. Cameron,et al.  MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. , 2002, American journal of clinical pathology.

[15]  K. Pienta,et al.  Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.

[16]  M. Perrais,et al.  TRANSCRIPTIONAL REGULATION OF THE 11 P 15 MUCIN GENES . TOWARDS NEW BIOLOGICAL TOOLS IN HUMAN THERAPY , IN INFLAMMATORY DISEASES AND CANCER ? , 2002 .

[17]  M. Hollingsworth,et al.  Overexpression of MUC1 reconfigures the binding properties of tumor cells , 2001, International journal of cancer.

[18]  S. Batra,et al.  Structural organization and classification of the human mucin genes. , 2001, Frontiers in bioscience : a journal and virtual library.

[19]  D L Rimm,et al.  Amplification of tissue by construction of tissue microarrays. , 2001, Experimental and molecular pathology.

[20]  A. Giatromanolaki,et al.  Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  H. L. Vos,et al.  A STAT-responsive Element in the Promoter of the Episialin/MUC1 Gene Is Involved in Its Overexpression in Carcinoma Cells* , 2001, The Journal of Biological Chemistry.

[22]  M. Copin,et al.  Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. , 2001, Human pathology.

[23]  M. Morse.  Technology evaluation: BLP-25, Biomira Inc. , 2001, Current opinion in molecular therapeutics.

[24]  相良 光久.  Expression of mucin 1(MUC1)in esophageal squamous-cell carcinoma : Its relationship with prognosis , 2001 .

[25]  M. Hollingsworth,et al.  Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti‐adhesion molecule , 2000, International journal of cancer.

[26]  K. Carraway,et al.  Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti‐adhesive glycoprotein , 2000, International journal of cancer.

[27]  S. Müller,et al.  MUC1: the polymorphic appearance of a human mucin. , 2000, Glycobiology.

[28]  A. Varki,et al.  New Aspects of Siglec Binding Specificities, Including the Significance of Fucosylation and of the Sialyl-Tn Epitope* , 2000, The Journal of Biological Chemistry.

[29]  D. Jocham,et al.  Technology evaluation: TG-1031, Transgene SA. , 2000, Current opinion in molecular therapeutics.

[30]  H. Denley,et al.  MUC1 Mucin Expression in Transitional Cell Carcinoma of the Bladder: A Target Antigen for Diagnosis and Therapy with Monoclonal Antibody C595 , 2000 .

[31]  J. Taylor‐Papadimitriou,et al.  MUC1 and cancer. , 1999, Biochimica et biophysica acta.

[32]  D. Chan,et al.  Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .

[33]  T. Irimura,et al.  Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients , 1999, British Journal of Cancer.

[34]  S. Kuduk,et al.  Probing cell-surface architecture through synthesis: an NMR-determined structural motif for tumor-associated mucins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Levine,et al.  MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage. , 1999, Molecular urology.

[36]  D. Kufe,et al.  Interaction of Glycogen Synthase Kinase 3β with the DF3/MUC1 Carcinoma-Associated Antigen and β-Catenin , 1998, Molecular and Cellular Biology.

[37]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[38]  N. Kohno,et al.  Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. , 1998, Cancer research.

[39]  V. Reuter,et al.  Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  I. Bièche,et al.  A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors. , 1997, Cancer genetics and cytogenetics.

[41]  M. Hollingsworth,et al.  Oligosaccharides Expressed on MUC1 Produced by Pancreatic and Colon Tumor Cell Lines* , 1997, The Journal of Biological Chemistry.

[42]  J. Wesseling,et al.  A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. , 1996, Molecular biology of the cell.

[43]  G. Hansson,et al.  Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl‐Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL‐60 leukocyte adhesion to E‐selectin‐expressing endothelial cells , 1996, Journal of cellular biochemistry.

[44]  D. Kufe,et al.  Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. , 1995, Cancer research.

[45]  Walsh,et al.  Prognostic significance of MUC1 epithelial mucin expression in breast cancer. , 1995, Human pathology.

[46]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[47]  S. Gendler,et al.  Epithelial mucin genes. , 1995, Annual review of physiology.

[48]  M. Hollingsworth,et al.  Expression of MUC1, MUC2, MUC3 and MUC4 mucin mrnas in human pancreatic and intestinal tumor cell lines , 1994, International journal of cancer.

[49]  R. Dahiya,et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.

[50]  F. Schröder,et al.  The TNM classification of prostate cancer , 1992, The Prostate. Supplement.

[51]  S. Hakomori,et al.  Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. , 1989, Advances in cancer research.

[52]  J. Rothbard,et al.  A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. , 1988, The Journal of biological chemistry.

[53]  H. Schulz.  [The TNM classification of pancreas cancer]. , 1988, Archiv fur Geschwulstforschung.

[54]  Gleason Df.  Classification of prostatic carcinomas. , 1966 .